Curia Global

Global CDMO with operations in the US, Europe, and India offering peptide drug substance development and manufacturing. Specializes in SPPS, LPPS, and hybrid peptide synthesis approaches. Acquired Snapdragon Chemistry for advanced peptide synthesis capabilities. Provides integrated solutions from development through commercial manufacturing. Note: peptide drug substance capability was not independently confirmed on the company website during verification; the SPPS/LPPS and Snapdragon Chemistry claims should be treated as unverified.

Directory assessment: Curia Global is listed as a CDMO in the peptide supply chain, serving Global markets from Global. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 1 source for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.